Skip to content
Forcyte Biotechnologies, Inc
Menu
  • About
  • Technology
  • Products & Services
  • Team
  • News
  • Contact

Category: Funding

Funding

Forcyte awarded Phase 2 SBIR by NIH / NCATS to develop pseudo-3D contractile “tissuoid” assay enabling study of coordinated cell contractions and tachyphylaxis

Forcyte has been awarded a $1.5M phase 2 SBIR to continue developing functional assays for cellular contractility to support programs in respiratory, hypertension, and many other indications where cellular force …

Funding

Forcyte awarded NIH funding for a FLECS-based uterine contractility model

Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the …

Funding

Forcyte awarded NIH Funding for a FLECS-based migraine model

Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the National Center for Complementary and Integrative Health (NCCIH), part of the National Institutes of Health …

Recent Posts

  • Forcyte awarded Phase 2 SBIR by NIH / NCATS to develop pseudo-3D contractile “tissuoid” assay enabling study of coordinated cell contractions and tachyphylaxis
  • New App Note covering FLECS Technology in collaboration with Molecular Devices is now available:
  • Forcyte’s Cardiac Tissuoid assay is now available
  • Forcyte Bio to participate in Innovation AveNEW for Startups Showcase at SLAS 2019
  • Forcyte awarded NIH funding for a FLECS-based uterine contractility model

Recent Comments

    Archives

    • September 2019
    • May 2019
    • January 2019
    • July 2018
    • April 2018
    • March 2018
    • November 2017

    Categories

    • Conferences
    • Funding
    • New Materials
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Copyright © 2017 Forcyte Biotechnologies, Inc